Reduced-Dose Systemic Fibrinolysis in Massive Pulmonary Embolism: A Pilot Study.

ABSTRACT:

Objective

Severe pulmonary embolism (PE) has a high mortality rate, which can be lowered by thrombolytic therapy (TT). However, full-dose TT is associated with major complications, including life-threatening bleeding. The aim of this study was to explore the efficacy and safety of extended, low-dose administration of tissue plasminogen activator (tPA) on in-hospital mortality and outcomes in massive PE.

Methods

This was a single-center, prospective cohort trial at a tertiary university hospital. A total of 37 consecutive patients with massive PE were included. A peripheral intravenous infusion was used to administer 25 mg of tPA over 6 hours. The primary endpoints were in-hospital mortality, major complications, pulmonary hypertension, and right ventricular dysfunction. The

SUBMITTER: Aykan AC 

PROVIDER: S-EPMC10579734 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature